LOOKING TO LEARN MORE ABOUT MEDICATIONS & MEDICAL CONDITIONS?
FOR EDUCATION ONLY - DISCUSS THE INFORMATION WITH YOUR HEALTHCARE PROVIDERS
Embedded Files
Chronic pain syndrome refers to pain that persists or recurs for more than 3 months, often accompanied by significant emotional distress and functional disability, and is now formally recognized in ICD-11 as a disease in its own right. [1-2] It affects approximately 1 in 5 US adults and is a leading cause of disability worldwide. [3-4]
Definition and Classification
The IASP, in cooperation with WHO, classifies chronic pain into seven groups: [1][5]
Chronic primary pain — pain not better accounted for by another condition (e.g., fibromyalgia, nonspecific low back pain, chronic widespread pain)
Chronic secondary pain — pain secondary to an underlying disease, including:
Chronic cancer-related pain
Chronic neuropathic pain
Chronic secondary visceral pain
Chronic posttraumatic and postsurgical pain
Chronic secondary headache and orofacial pain
Chronic secondary musculoskeletal pain
Chronic primary pain is diagnosed when pain has persisted for more than 3 months, is associated with significant emotional distress and/or functional disability, and is not better explained by another diagnosis. [6]
Pathophysiology
Chronic pain is now understood through a biopsychosocial model involving dynamic interactions among biological, psychological, and social factors. [3]
Three mechanistic pain categories are recognized: [7-8]
Nociceptive pain — ongoing tissue injury or threatened damage
Neuropathic pain — injury or disease of the peripheral or central nervous system
Nociplastic pain — altered nociceptive function without clear tissue or nerve damage, driven by central sensitization
Central sensitization involves amplified ascending (excitatory) signaling and reduced descending (inhibitory) signaling in the CNS, leading to hyperalgesia and allodynia. [7][9]
Key pathologic processes include glial cell activation, neuroinflammation (TNF-α, IL-1β), ion channel dysregulation, epigenetic modifications, and maladaptive neuroplasticity. [10-11]
Psychological factors (depression, anxiety, catastrophizing) and social adversity further modulate these processes, creating self-reinforcing feedback loops. [3][10]
Clinical Assessment
A comprehensive biopsychosocial pain assessment should include:
[5]
Pain characteristics (onset, location, duration, quality, exacerbating/relieving factors, radiation, 24-hour pattern)
History of previous treatments and their effects
Impact on daily functioning and quality of life
Functional goals
Screening for psychological comorbidities (depression, anxiety, PTSD, substance use)
Management
Current guidelines uniformly recommend a multimodal, stepped-care approach prioritizing nonpharmacologic and nonopioid therapies.
[3][12-13]
First-line: Nonpharmacologic therapies
Exercise therapy — high-quality evidence for reducing pain and improving function in low back pain, osteoarthritis, and fibromyalgia, with benefits sustained 2–6 months
[13]
Cognitive behavioral therapy (CBT) — positive effects on disability and catastrophizing; recommended by APA, CDC, NICE, and SIGN guidelines
[12][14]
Mindfulness-based stress reduction (MBSR) — evidence for low back pain and fibromyalgia
[13]
Other modalities with evidence: acupuncture, massage, spinal manipulation, multidisciplinary rehabilitation, yoga, tai chi
[13]
Category 1 — Very large molecules>1,000 g/mol
1.Botulinum toxin A~150,000 g/molNeurotoxin; focal neuropathic pain; injected locally
Category 2 — Large molecules300–500 g/mol
2.Indomethacin358 g/molNSAID; inflammatory pain
3.Piroxicam331 g/molNSAID; acute musculoskeletal pain
4.Cannabidiol (CBD)314 g/molCannabinoid; peripheral neuropathy; limited evidence
5.Δ9-THC314 g/molCannabinoid; neuropathic pain; bioavailability concerns topically
6.Capsaicin305 g/molTRPV1 agonist; neuropathic pain (NNT 10.6 for 8% patch)
7.Diclofenac296 g/molNSAID; OA, sprains (NNT 1.8–5.0); best-studied topical NSAID
8.Bupivacaine288 g/molLocal anesthetic; compounded formulations
9.Doxepin279 g/molTricyclic antidepressant; neuropathic pain, pruritus
10.Amitriptyline277 g/molTricyclic antidepressant; compounded neuropathic pain
11.Tetracaine264 g/molLocal anesthetic; topical anesthesia
12.Arnica (helenalin)262 g/molHerbal; bruises, muscle soreness
13.Ketoprofen254 g/molNSAID; sprains, strains, OA; good evidence
14.Phenytoin252 g/molAnticonvulsant; compounded neuropathic pain
Category 3 — Medium molecules200–299 g/mol
15.Flurbiprofen244 g/molNSAID; musculoskeletal pain
16.Ketamine238 g/molNMDA antagonist; compounded neuropathic pain
17.Lidocaine234 g/molLocal anesthetic; neuropathic pain (NNT 4.4); first-line topical
18.Naproxen230 g/molNSAID; musculoskeletal pain
19.Clonidine230 g/molAlpha-2 agonist; compounded neuropathic pain
20.Glyceryl trinitrate (nitroglycerin)227 g/molVasodilator; rotator cuff tendinopathy; diabetic neuropathy
21.Prilocaine220 g/molLocal anesthetic; EMLA cream (with lidocaine)
22.Baclofen214 g/molGABA-B agonist; compounded neuropathic pain
23.Ibuprofen206 g/molNSAID; musculoskeletal pain
Category 4 — Small molecules150–199 g/mol
24.Gabapentin171 g/molAnticonvulsant; compounded neuropathic pain
25.Benzocaine165 g/molLocal anesthetic; superficial pain/itch
26.Eugenol (clove oil)164 g/molNatural/essential oil; dental/muscle pain
27.Menthol156 g/molCounterirritant; muscle aches, cooling sensation
28.Camphor152 g/molCounterirritant; muscle pain, rubefacient
29.Methyl salicylate152 g/molSalicylate; muscle/joint pain
Category 5 — Very small molecules<150 g/mol
30.Salicylic acid138 g/molSalicylate; rubefacient, keratolytic
🔑 Key clinical pearls
Optimal skin penetration: molecules <500 Da + moderate lipophilicity; all except botulinum toxin meet this criterion
Best evidence (SORT A): diclofenac, ketoprofen, lidocaine 5%, capsaicin 8%
Compounded formulations (ketamine, baclofen, gabapentin, amitriptyline) cost ~$55–150/month; not insurance-covered
OTHER COMMON TOPICALS..
OTHER COMMON TOPICALS..
LIST #1
Category 1 — Macromolecules & steroids>400 g/mol
1.Tacrolimus (Protopic)804 g/molCalcineurin inhibitor; eczema/psoriasis
2.Halobetasol propionate485 g/molSuper-potent corticosteroid; psoriasis
3.Clobetasol propionate467 g/molSuper-potent corticosteroid; Class I
4.Betamethasone dipropionate504 g/molPotent corticosteroid; Class II
5.Fluocinonide495 g/molPotent corticosteroid; dermatitis
6.Triamcinolone acetonide434 g/molMid-potency corticosteroid; Class III–IV
7.Mometasone furoate521 g/molMid-potency corticosteroid; Class IV
8.Hydrocortisone butyrate432 g/molMid-potency corticosteroid; Class V
9.Tretinoin (retinoic acid)300 g/molRetinoid; acne, photoaging; borderline large
10.Calcipotriene (Dovonex)412 g/molVitamin D analogue; psoriasis
Category 2 — Antifungals & antivirals250–450 g/mol
11.Econazole nitrate444 g/molAzole antifungal; tinea, candida
12.Ketoconazole531 g/molAzole antifungal; seborrheic dermatitis
13.Clotrimazole344 g/molAzole antifungal; tinea, candida
14.Miconazole416 g/molAzole antifungal; OTC tinea/candida
15.Terbinafine (Lamisil)291 g/molAllylamine antifungal; onychomycosis
16.Acyclovir (topical)225 g/molAntiviral; HSV labialis; limited penetration
17.Penciclovir (Denavir)253 g/molAntiviral; cold sores; better topical than acyclovir
18.Imiquimod (Aldara)240 g/molImmune modifier; genital warts, AK
Category 3 — Antibiotics & antiseptics150–500 g/mol
19.Mupirocin (Bactroban)501 g/molAntibiotic; impetigo, MRSA decolonization
20.Fusidic acid516 g/molAntibiotic; staphylococcal skin infections
21.Clindamycin (topical)425 g/molAntibiotic; acne vulgaris
22.Metronidazole (topical)171 g/molAntibiotic; rosacea; small molecule
23.Erythromycin (topical)734 g/molMacrolide antibiotic; acne; very large
24.Neomycin sulfate615 g/molAminoglycoside; wound infections; high sensitization
25.Bacitracin~1,423 g/molPolypeptide antibiotic; OTC wound care
26.Povidone-iodine~2,364 g/molAntiseptic polymer-iodine complex; wound care
27.Chlorhexidine505 g/molAntiseptic; wound/skin disinfection
Category 4 — Dermatologics & vasodilators100–350 g/mol
28.Minoxidil209 g/molVasodilator; alopecia; Rogaine
29.Finasteride (topical)373 g/mol5α-reductase inhibitor; compounded hair loss
30.Hydroquinone110 g/molDepigmenting agent; melasma; very small
31.Azelaic acid188 g/molDicarboxylic acid; rosacea, acne, melasma
32.Benzoyl peroxide242 g/molOxidizing agent; acne; bactericidal
33.Pimecrolimus (Elidel)810 g/molCalcineurin inhibitor; atopic dermatitis; large
34.Coal tar~variableComplex mixture; psoriasis, seborrheic dermatitis
Category 5 — Ophthalmics & small actives<250 g/mol
35.Timolol (ophthalmic)316 g/molBeta-blocker; glaucoma eye drops
36.Latanoprost432 g/molProstaglandin analogue; glaucoma
37.Brimonidine (Mirvaso)292 g/molAlpha-2 agonist; rosacea erythema; topical gel
38.Fluorouracil (5-FU)130 g/molAntimetabolite; actinic keratosis; Efudex
39.Urea (40%)60 g/molKeratolytic; hyperkeratosis; smallest common topical
40.Lactic acid90 g/molAHA keratolytic; ichthyosis, xerosis
LIST #2
🔬 CATEGORY 1: Large Molecules — Near/Above 500 Da Limit (Poor Penetration)
Tacrolimus — 804 g/mol — Calcineurin inhibitor; atopic dermatitis (requires thin skin for absorption)
[1]
Cyclosporine (topical) — 1,203 g/mol — Immunosuppressant; poor topical penetration confirms 500 Da rule
[1]
Mupirocin — 501 g/mol — Antibiotic; impetigo, MRSA decolonization
[3]
Pimecrolimus — 810 g/mol — Calcineurin inhibitor; atopic dermatitis
[1]
Nystatin — 926 g/mol — Polyene antifungal; cutaneous candidiasis (works on surface only)
[4]
🧪 CATEGORY 2: Corticosteroids (360–525 g/mol)
Clobetasol propionate — 467 g/mol — Class I (super-potent); psoriasis, severe eczema
[5]
Halobetasol propionate — 485 g/mol — Class I (super-potent); psoriasis
[5]
Betamethasone dipropionate — 504 g/mol — Class I–II; psoriasis, dermatitis
[5]
Fluocinonide — 495 g/mol — Class II (high potency); eczema, dermatitis
[5]
Triamcinolone acetonide — 434 g/mol — Class II–IV; versatile mid-potency steroid
[5]
Mometasone furoate — 521 g/mol — Class II–IV; dermatitis, psoriasis
[5]
Fluticasone propionate — 501 g/mol — Class III–V; eczema, dermatitis
[5]
Hydrocortisone acetate — 405 g/mol — Class VII (lowest potency); mild dermatitis
[5-7]
Hydrocortisone — 362 g/mol — Class VII; OTC anti-itch, mild eczema
[6-7]
Desonide — 416 g/mol — Class VI (low potency); pediatric eczema
[5]
💊 CATEGORY 3: Antibiotics & Antiseptics (130–480 g/mol)
Fusidic acid — 517 g/mol — Antibiotic; staphylococcal skin infections
[8]
Erythromycin (topical) — 734 g/mol — Antibiotic; acne (surface action)
[3]
Clindamycin — 425 g/mol — Antibiotic; acne vulgaris
[9]
Metronidazole — 171 g/mol — Antibiotic/anti-inflammatory; rosacea
Bacitracin — 1,423 g/mol — Antibiotic; wound care (surface action only)
[3]
Neomycin — 615 g/mol — Antibiotic; wound care (contact dermatitis risk)
[3]
Benzoyl peroxide — 242 g/mol — Antimicrobial/keratolytic; acne
[9]
Silver sulfadiazine — 357 g/mol — Antimicrobial; burn wounds
🍄 CATEGORY 4: Antifungals (250–450 g/mol)
Ketoconazole — 531 g/mol — Azole antifungal; seborrheic dermatitis, tinea
[4][10]
Clotrimazole — 345 g/mol — Azole antifungal; tinea, candidiasis
[10-11]
Miconazole — 416 g/mol — Azole antifungal; tinea, candidiasis
[8][10]
Terbinafine — 291 g/mol — Allylamine antifungal (fungicidal); tinea pedis, corporis
[10][12]
Ciclopirox — 207 g/mol — Hydroxypyridone; onychomycosis, seborrheic dermatitis
[12]
Efinaconazole — 348 g/mol — Azole; onychomycosis (newer agent)
[12]
Tavaborole — 152 g/mol — Oxaborole; onychomycosis (smallest antifungal)
[12]
🧴 CATEGORY 5: Retinoids & Other Dermatologics (150–350 g/mol)
Tretinoin (all-trans retinoic acid) — 300 g/mol — Retinoid; acne, photoaging
[13]
Adapalene — 412 g/mol — Synthetic retinoid; acne (anti-inflammatory)
[13]
Tazarotene — 351 g/mol — Retinoid prodrug; acne, psoriasis
[13]
Hydroquinone — 110 g/mol — Depigmenting agent; melasma, PIH
[9]
Azelaic acid — 188 g/mol — Anti-inflammatory/tyrosinase inhibitor; rosacea, PIH
[9]
Calcipotriol (calcipotriene) — 413 g/mol — Vitamin D analog; psoriasis
Roflumilast — 403 g/mol — PDE4 inhibitor; psoriasis, seborrheic dermatitis
[14]
5-Fluorouracil — 130 g/mol — Antimetabolite; actinic keratoses, superficial BCC
Imiquimod — 240 g/mol — Immune response modifier; actinic keratoses, BCC, warts
Minoxidil — 209 g/mol — Vasodilator; androgenetic alopecia
Key Takeaway — The 500 Dalton Rule:
Molecules <500 Da penetrate skin effectively; virtually all successful topical drugs fall below this threshold.
[1]
Notable exceptions (tacrolimus 804 Da, pimecrolimus 810 Da) work because they are applied to disrupted skin barriers in eczema, not intact skin.
[1]
This rule is critical when evaluating whether a compound can realistically achieve therapeutic concentrations topically.
[2]
Page updated
Google Sites
Report abuse